林业发展局警告Savannah Chrisley纠正有关她体重损失地点药物的虚假说法,这些药物未经林业发展局核准。 The FDA warned Savannah Chrisley to fix false claims about her weight-loss site’s drugs, which are not FDA-approved.

美国食品和药物管理局 (FDA) 在她的减肥网站GoodGirlRX上向萨凡娜·克里斯利发出警告,反对称合成GLP-1药物如西马格卢提德和提泽帕提德是"FDA批准"或"临床证明",并指出这些产品未经FDA批准,缺乏评估的安全性和有效性. The FDA issued a warning to Savannah Chrisley over her weight-loss website GoodGirlRX, objecting to claims that compounded GLP-1 drugs like semaglutide and tirzepatide were "FDA-approved" or "clinically proven," noting these products are not FDA-approved and lack evaluated safety and effectiveness. 该机构给了她15个工作日来纠正语言,警告可能采取的法律行动。 The agency gave her 15 business days to correct the language, warning of potential legal action. Chrisley更新了网站内容, 以「临床研究」取代「临床证明」, 并增加免责声明, 指出问题仅涉及网站措辞, Chrisley updated her site to replace "clinically proven" with "clinically studied" and added disclaimers, stating the issue involved only website wording, not patient safety, and confirmed no fines were imposed. 她肯定了她的公司承诺将妇女与领有执照的医生联系起来,并欢迎林业发展局的指导。 She affirmed her company’s commitment to connecting women with licensed physicians and welcomed the FDA’s guidance.